Proactive Investors - Run By Investors For Investors

Supreme Pharma makes marked progress in latest nine months

Meanwhile, the group ended the period with $2.75mln compared to $107,000 at the end of March last year.
Pictured is a Supreme growing facility
Several milestones have been toppled by the group this year and it opened a seven acre hybrid greenhouse facility in Kincardine, Ontario at the end of March, where first seeds were then sown

Medical marijuana firm Supreme Pharmaceuticals Inc (CSE:SL) increased its cash position and narrowed the loss in the nine months to end March - a period in which it made considerable progress, it told investors.

The net loss for the period was $3.08mln against a loss of $4.76mln in the same period last year, it said.

Meanwhile, the group ended the period with $2.75mln compared to $107,000 at the end of March last year.

Several milestones have been toppled by the group this year and it opened a seven acre hybrid greenhouse facility in Kincardine, Ontario at the end of March, where first seeds were then sown.

That came after the firm obtained the key Marijuana for Medical Purposes (MMPR) licence, which was also granted in March.

The  plants are now progressing nicely towards an initial harvest which is expected in the third quarter, 2016.

Supreme also raised additional capital through the use of two warrant incentive programmes generating total proceeds of over $3.1mln.

The cash will be used for general working capital purposes as the firm moves through the cultivation stage in advance of expected revenues in the fourth quarter of 2016, it said.

Earlier this month, the group said it had secured letters of intent (LOIs) with five licenced producers over the long term supply of marijuana.

If they turn into definite agreements, it would mean the sale of more than 250kg of dried marijuana and 70 kg of dried marijuana trim in 2016, representing pretty much all of the group subsidiary's anticipated production for 2016, the firm told investors.

In addition, the agreements will be renewable for successive one-year periods.

View full SL profile View Profile

Supreme Pharmaceuticals Timeline

Related Articles

patch
Sun
The New Jersey company's lead product is Twirla, a low-dose prescription contraceptive applied once weekly for three weeks, followed by a week without the patch
Cancer cells
June 27 2018
The Nottingham-based privately-owned company has made an impressive fist of developing the OMIS (Opto-magnetic Imaging Spectroscopy) cancer detection system
scientist at petrie dish
May 15 2019
Here we take a closer look at Midatech Pharma PLC (LON:MTPH)
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use